$9676 | SAVE $1,319 | Single User
$19351 | SAVE $2,639 | Site License
$29027 | SAVE $3,958 | Enterprise License

PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
[Published by Global Data]

Published by Global Data: 01 Nov 2015 | 17995 | In Stock
Related Topics: Multiple Myeloma , Myeloma

Introduction

PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

Summary

The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.

Highlights

Key Questions Answered

- The multiple myeloma market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of multiple myeloma market?

- The late-stage multiple myeloma pipeline has therapies targeting different multiple myeloma populations. Which late-stage drugs will have the biggest impact in each patient population? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

- The current multiple myeloma market is dominated by Velcade and Revlimid. How will the advent of new mAbs change the drug treatment landscape for multiple myeloma? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?

Key Benefits

- The main driver of the enormous expansion of the multiple myeloma market will be the launch of mAbs Empliciti and daratumumab.

- The second largest driver will be the label extension of currently marketed drugs Kyprolis and Revlimid.

- Another driver of the multiple myeloma market will be the ageing population in the 8MM, which will increase the number of multiple myeloma cases.

- The increase in therapeutic options overall will lead to increases in treatment rates in the 8MM. Also, as triplet/quadruplet therapies increasingly become the standard of care within the forecast period, this will increase the duration of treatment for each patient as well as the number of treatments each patient receives.

Scope

- Overview of multiple myeloma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized multiple myeloma therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the multiple myeloma therapeutics market.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the global multiple myeloma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop business strategies by understanding the trends shaping and driving the global multiple myeloma therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global multiple myeloma therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global multiple myeloma therapeutics market from 2013-2023.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 11

    1.1 List of Tables 17

    1.2 List of Figures 23

    2 Introduction 25

    2.1 Catalyst 25

    2.2 Related Reports 26

    2.3 Upcoming Related Reports 26

    3 Disease Overview 27

    3.1 Etiology and Pathophysiology 27

    3.1.1 Etiology 27

    3.1.2 Pathophysiology 27

    3.2 Staging Systems 30

    3.3 Response and Relapse Criteria 31

    3.4 Symptoms 33

    3.5 Prognosis 34

    3.6 Quality of Life 35

    4 Epidemiology 38

    4.1 Disease Background 38

    4.2 Risk Factors and Comorbidities 39

    4.3 Global Trends 40

    4.3.1 Incidence 40

    4.3.2 Survival Rates for Multiple Myeloma - 8MM 43

    4.4 Forecast Methodology 44

    4.4.1 Sources Used 46

    4.4.2 Sources Not Used 48

    4.4.3 Forecast Assumptions and Methods, Multiple Myeloma Diagnosed Incident Cases 48

    4.4.4 Forecast Assumptions and Methods, Multiple Myeloma Five-Year Diagnosed Prevalent Cases 49

    4.4.5 Forecast Assumptions and Methods, Multiple Myeloma Clinical Stages at Diagnosis 50

    4.5 Epidemiological Forecast for Multiple Myeloma (2013-2023) 50

    4.5.1 Diagnosed Incident Cases of Multiple Myeloma 50

    4.5.2 Age-Specific Diagnosed Incident Cases of Multiple Myeloma 52

    4.5.3 Sex-Specific Diagnosed Incident Cases of Multiple Myeloma 54

    4.5.4 Age-Standardized Diagnosed Incidence of Multiple Myeloma 56

    4.5.5 Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis 57

    4.5.6 Five-Year Diagnosed Prevalent Cases of Multiple Myeloma 58

    4.6 Discussion 60

    4.6.1 Epidemiological Forecast Insight 60

    4.6.2 Limitations of the Analysis 60

    4.6.3 Strengths of the Analysis 61

    5 Disease Management 62

    5.1 Treatment Overview 62

    5.2 Diagnosis 63

    5.3 Clinical Practice 64

    5.3.1 Primary Therapy for SCT-Eligible Patients 65

    5.3.2 Primary Therapy for Non-SCT Patients 67

    5.3.3 Salvage/Relapse Therapy 68

    5.3.4 Leading Prescribed Drugs 69

    5.4 US 71

    5.4.1 Diagnosis 72

    5.4.2 Clinical Practice 73

    5.5 France 75

    5.5.1 Diagnosis 76

    5.5.2 Clinical Practice 77

    5.6 Germany 77

    5.6.1 Diagnosis 79

    5.6.2 Clinical Practice 79

    5.7 Italy 79

    5.7.1 Diagnosis 81

    5.7.2 Clinical Practice 81

    5.8 Spain 83

    5.8.1 Diagnosis 84

    5.8.2 Clinical Practice 84

    5.9 UK 85

    5.9.1 Diagnosis 86

    5.9.2 Clinical Practice 87

    5.10 Japan 87

    5.10.1 Diagnosis 88

    5.10.2 Clinical Practice 89

    5.11 China (Urban) 90

    5.11.1 Diagnosis 91

    5.11.2 Clinical Practice 92

    6 Competitive Assessment 93

    6.1 Overview 93

    6.2 Product Profiles - Proteasome Inhibitors 93

    6.2.1 Velcade (Bortezomib) 93

    6.2.2 Kyprolis (Carfilzomib) 100

    6.3 Product Profiles - Immunomodulators 108

    6.3.1 Revlimid (Lenalidomide) 108

    6.3.2 Pomalyst/Imnovid (Pomalidomide) 115

    6.4 Other Therapeutic Classes 120

    7 Unmet Need and Opportunity 121

    7.1 Overview 121

    7.2 Treatment of High-Risk Patients 121

    7.2.1 Unmet Need 121

    7.2.2 Gap Analysis 122

    7.2.3 Opportunity 123

    7.3 Treatment of Patients with Smoldering Myeloma 123

    7.3.1 Unmet Need 123

    7.3.2 Gap Analysis 125

    7.3.3 Opportunity 125

    7.4 Treatment of Extramedullary Disease 126

    7.4.1 Unmet Need 126

    7.4.2 Gap Analysis 126

    7.4.3 Opportunity 127

    8 Pipeline Assessment 128

    8.1 Overview 128

    8.2 Promising Drugs in Clinical Development 128

    8.2.1 Farydak (Panobinostat) 128

    8.2.2 Ixazomib 135

    8.2.3 Empliciti (Elotuzumab) 140

    8.2.4 Daratumumab 146

    8.2.5 Aplidin (Plitidepsin) 151

    8.3 Promising Drugs in Early-Stage Development 155

    8.3.1 Oprozomib (ONX-0912) 155

    8.3.2 Filanesib 156

    8.3.3 SAR650984 156

    8.3.4 Marizomib 158

    8.3.5 Evofosfamide 158

    8.3.6 LGH447 159

    8.3.7 Selinexor (KPT-330) 159

    9 Current and Future Players 161

    9.1 Overview and Trends in Corporate Strategy 161

    9.2 Company Profiles 164

    9.2.1 Millennium Pharmaceuticals/Takeda 164

    9.2.2 Celgene 166

    9.2.3 Onyx Pharmaceuticals/Amgen 168

    9.2.4 Novartis 169

    9.2.5 AbbVie 171

    9.2.6 Bristol-Myers Squibb 172

    9.2.7 Janssen 173

    10 Market Outlook 175

    10.1 Global Markets 175

    10.1.1 Forecast 175

    10.1.2 Drivers - Global Issues 182

    10.1.3 Barriers - Global Issues 183

    10.2 US 184

    10.2.1 Forecast 184

    10.2.2 Key Events 188

    10.2.3 Drivers - US 188

    10.2.4 Barriers - US 190

    10.3 5EU 191

    10.3.1 Forecast 191

    10.3.2 Key Events 196

    10.3.3 Drivers - 5EU 196

    10.3.4 Barriers - 5EU 198

    10.4 Japan 200

    10.4.1 Forecast 200

    10.4.2 Key Events 203

    10.4.3 Drivers - Japan 203

    10.4.4 Barriers - Japan 204

    10.5 China (Urban) 205

    10.5.1 Forecast 205

    10.5.2 Key Events 208

    10.5.3 Drivers - China (Urban) 208

    10.5.4 Barriers - China (Urban) 209

    11 Appendix 211

    11.1 Bibliography 211

    11.2 Abbreviations 233

    11.3 Methodology 237

    11.4 Forecasting Methodology 237

    11.4.1 Diagnosed Multiple Myeloma Patients 237

    11.4.2 Percent of Drug-Treated Patients 238

    11.4.3 Drugs Included in Each Therapeutic Class 238

    11.4.4 Launch and Patent Expiry Dates 239

    11.4.5 General Pricing Assumptions 240

    11.4.6 Individual Drug Assumptions 241

    11.4.7 Pricing of Pipeline Agents 248

    11.4.8 Generic Erosion 255

    11.5 Primary Research - KOLs Interviewed for this Report 256

    11.6 Primary Research - High-Prescriber Survey 258

    11.7 About the Authors 259

    11.7.1 Analyst 259

    11.7.2 Therapy Director 259

    11.7.3 Epidemiologist 259

    11.7.4 Global Head of Healthcare 260

    11.8 About GlobalData 261

    11.9 Disclaimer 261

List Of Tables
in PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.1 List of Tables

Table 1: Definition of the Classes of Myeloma 29

Table 2: Staging Systems for Multiple Myeloma 31

Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response 32

Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression 32

Table 5: Symptoms of Multiple Myeloma 33

Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma 34

Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression 35

Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma 35

Table 9: Multiple Myeloma Clinical Stages at Diagnosis, Using the ISS Criteria 39

Table 10: Risk Factors and Comorbidities for Multiple Myeloma 40

Table 11: Trends in the Age-Adjusted Incidence of Multiple Myeloma in the US, Ages ≥40 Years, 1993-2007 41

Table 12: Trends in the Age-Adjusted Incidence of Multiple Myeloma in the 5EU, Ages ≥40 Years, 1993-2007 42

Table 13: Trends in the Age-Adjusted Incidence of Multiple Myeloma in Japan, Ages ≥40 Years, 1993-2007 42

Table 14: Trends in the Age-Adjusted Incidence of Multiple Myeloma in Urban China, Ages ≥40 Years, 1993-2007 43

Table 15: Trends in the Five-Year Relative Survival (%) of Multiple Myeloma in the 8MM, Both Sexes, 1993-2009 44

Table 16: 8MM, Sources of Epidemiological Data Used for the Forecast for Multiple Myeloma Diagnosed Incident Cases 45

Table 17: 8MM, Sources of Epidemiological Data Used for the Forecast for Multiple Myeloma Diagnosed Five-Year Prevalent Cases 45

Table 18: 8MM, Sources of Epidemiological Data Used for the Segmentation of Multiple Myeloma Incident Cases by Clinical Stage at Diagnosis 46

Table 19: 8MM, Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, Ages ≥40 Years, N, 2013-2023 51

Table 20: 8MM, Age-Specific Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, N (Row %), 2013 53

Table 21: 8MM, Sex-Specific Diagnosed Incident Cases of Multiple Myeloma, Ages ≥40 Years, N (Row %), 2013 55

Table 22: 8MM, Five-Year Diagnosed Prevalent Cases of Multiple Myeloma, Both Sexes, Ages ≥40 Years, N, 2013-2023 59

Table 23: Treatment Guidelines for Multiple Myeloma 63

Table 24: Definition of the Classes of Myeloma 64

Table 25: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014 69

Table 26: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013 70

Table 27: Country Profile - US 72

Table 28: Country Profile - France 75

Table 29: Country Profile - Germany 78

Table 30: Country Profile - Italy 80

Table 31: Country Profile - Spain 83

Table 32: Country Profile - UK 86

Table 33: Country Profile - Japan 88

Table 34: Country Profile - China (Urban) 91

Table 35: Product Profile - Velcade 94

Table 36: Results from the Pivotal Phase III APEX Trial for Velcade 96

Table 37: Results from the Pivotal Phase III VISTA Trial for Velcade 97

Table 38 Results from the Subcutaneous versus Intravenous Velcade Phase III trial 97

Table 39: Common Grade 3 and 4 Adverse Events from Velcade Pivotal Clinical Trials 98

Table 40: Velcade SWOT Analysis, 2015 99

Table 41: Global Sales Forecast ($m) for Velcade, 2013-2023 99

Table 42: Product Profile - Kyprolis 101

Table 43 Summary of Phase III Pivotal Trial Results for Kyprolis 104

Table 44: Summary of Phase II Clinical Trial Efficacy Data for Kyprolis 105

Table 45 Summary of Adverse Events from Key Phase III Pivotal Trials for Kyprolis 106

Table 46: Kyprolis SWOT Analysis, 2015 107

Table 47: Global Sales Forecasts ($m) for Kyprolis, 2013-2023 108

Table 48: Product Profile - Revlimid 109

Table 49 Summary of Phase III Pivotal Trial Results for Revlimid in NDMM Patients 111

Table 50 Summary of Phase III Pivotal Trial Results for Revlimid in RRMM Patients 112

Table 51: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Revlimid 113

Table 52: Revlimid SWOT Analysis, 2015 114

Table 53: Global Sales Forecast ($m) for Revlimid, 2013-2023 114

Table 54: Product Profile - Pomalyst 115

Table 55: Summary of PFS, OS, and ORR from Phase II Trial Data for Pomalyst 117

Table 56: Summary of Phase III Trial Data for Pomalyst 118

Table 57: Pomalyst SWOT Analysis, 2015 119

Table 58: Global Sales Forecasts ($m) for Pomalyst, 2013-2023 119

Table 59: Summary of Other Therapeutic Classes, 2015 120

Table 60: Pipeline Product Profile - Farydak 129

Table 61: Summary of the Phase III PANORAMA 1 Trial of Farydak 132

Table 62: Summary of the Phase III PANORAMA 1 Trial of Farydak in Patients Who Recived at Least Two Prior Lines of Therapy (Including Velcade and an IMiD) 132

Table 63: Summary of the Phase II PANORAMA 2 Trial of Farydak 133

Table 64: Grade 3-4 Adverse Events in the Phase III PANORAMA 1 Trial of Farydak 133

Table 65: Farydak SWOT Analysis, 2015 135

Table 66: Global Sales Forecast ($m) for Farydak, 2013-2023 135

Table 67: Pipeline Product Profile - Ixazomib 136

Table 68: Response Results from the Phase II Study of Ixazomib 138

Table 69: Ixazomib SWOT Analysis, 2015 139

Table 70: Global Sales Forecast ($m) for Ixazomib, 2013-2023 140

Table 71: Pipeline Product Profile - Empliciti 141

Table 72: Summary of the Phase III ELOQUENT 2 trial of Empliciti 143

Table 73: Efficacy Results from the Phase II Study of Empliciti with Velcade and Dexamethasone 144

Table 74: Empliciti SWOT Analysis, 2015 145

Table 75: Global Sales Forecast ($m) for Empliciti, 2013-2023 145

Table 76: Pipeline Product Profile - Daratumumab 146

Table 77: Response Results from the Phase II Study of Daratumumab 148

Table 78: Daratumumab SWOT Analysis, 2015 150

Table 79: Global Sales Forecast ($m) for Ddaratumumab, 2013-2023 150

Table 80: Pipeline Product Profile - Aplidin 151

Table 81: Summary of Phase II Clinical Trial Results for Aplidin 153

Table 82: Summary of Grade 3 and 4 Adverse Events of Aplidin 153

Table 83: Aplidin SWOT Analysis, 2015 154

Table 84: Global Sales Forecast ($m) for Aplidin, 2013-2023 154

Table 85: Summary of Efficacy Data from the Phase Ib/II Clinical Trial of Oprozomib 156

Table 86: Summary of the Phase I Efficacy Results of SAR650984 157

Table 87: Summary of the Phase I Efficacy Results of Evofosfamide 159

Table 88: Key Companies in the Multiple Myeloma Market Across the 8MM, 2013-2023 162

Table 89: Millennium Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015 166

Table 90: Celgene’s Multiple Myeloma Therapy Portfolio Assessment, 2015 168

Table 91: Onyx Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015 169

Table 92: Novartis’ Multiple Myeloma Therapy Portfolio Assessment, 2015 171

Table 93: AbbVie’s Multiple Myeloma Therapy Portfolio Assessment, 2015 172

Table 94: BMS’ Multiple Myeloma Therapy Portfolio Assessment, 2015 173

Table 95: Janssen’s Multiple Myeloma Therapy Portfolio Assessment, 2015 174

Table 96: Annual Global Sales ($m) for Multiple Myeloma by Region, 2013-2023 176

Table 97: Annual Global Sales ($m) for Multiple Myeloma by Drug, 2013-2023 179

Table 98: Global Multiple Multiple Myeloma - Drivers, 2013-2023 182

Table 99: Global Multiple Multiple Myeloma - Barriers, 2013-2023 183

Table 100: US Sales Forecast, Multiple Myeloma, 2013-2023 ($m) 185

Table 101: Key Events Impacting Sales for Multiple Myeloma in the US, 2013-2023 188

Table 102: US Multiple Myeloma - Drivers, 2013-2023 188

Table 103: US Multiple Myeloma - Barriers, 2013-2023 190

Table 104: 5EU Sales Forecast, Multiple Myeloma, 2013-2023 ($m) 192

Table 105: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2013-2023 196

Table 106: 5EU Multiple Myeloma - Drivers and Barriers, 2013-2023 196

Table 107: 5EU Multiple Myeloma - Barriers, 2013-2023 198

Table 108: Japan Sales Forecasts, Multiple Myeloma, 2013-2023 ($m) 201

Table 109: Key Events Impacting Sales for Multiple Myeloma in Japan, 2013-2023 203

Table 110: Japanese Multiple Myeloma - Drivers, 2013-2023 203

Table 111: Japanese Multiple Myeloma - Barriers, 2013-2023 204

Table 112: China (Urban) Sales Forecast, Multiple Myeloma, 2013-2023 ($m) 206

Table 113: Key Events Impacting Sales for Multiple Myeloma in China 2013-2023 208

Table 114: Chinese (Urban) Multiple Myeloma - Drivers, 2013-2023 208

Table 115: Chinese (Urban) Multiple Myeloma - Barriers, 2013-2023 209

Table 116: Multiple Myeloma Diagnosed Incidence, 2013-2023 238

Table 117: Multiple Myeloma Drugs and Pipeline agents, Launch Dates 239

Table 118: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries 240

Table 119: Average Cost of Therapy for Velcade 242

Table 120: Average Duration of Treatment (Weeks) for Velcade 242

Table 121: Average Cost of Therapy for Kyprolis ($) 244

Table 122: Average Duration of Treatment (Weeks) for Kyprolis 244

Table 123: Average Cost of Therapy for Revlimid ($) 245

Table 124: Average Duration of Treatment (Weeks) for Revlimid 246

Table 125: Average Cost of Therapy for Pomalyst/Imnovid ($) 247

Table 126 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid 247

Table 127: Average Cost of Therapy for Farydak ($) 248

Table 128: Duration of Treatment (Weeks) for Farydak 249

Table 129: Average Cost of Therapy for Ixazomib ($) 250

Table 130: Duration of Treatment (Weeks) for Ixazomib 250

Table 131: Average Cost of Therapy for Empliciti ($) 251

Table 132: Duration of Treatment (Weeks) for Empliciti 252

Table 133: Average Cost of Therapy for Daratumumab ($) 253

Table 134: Duration of Treatment (Weeks) for Daratumumab 254

Table 135: Average Cost of Therapy for Daratumumab ($) 255

Table 136: Duration of Treatment (Weeks) for Daratumumab 255

Table 137: Numbers of Prescribers Surveyed in Each Country 258

List Of Figures, Charts and Diagrams
in PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.2 List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, Ages ≥40 Years, N, 2013-2023 52

Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, N, 2013 54

Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of Multiple Myeloma, Ages ≥40 Years, N, 2013 56

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of Multiple Myeloma (Cases per 100,000 Population), Ages ≥40 Years, by Sex, 2013 57

Figure 5: 8MM, Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis, Ages ≥40 Years, N, 2013 58

Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of Multiple Myeloma, Both Sexes, Ages ≥40 Years, N, 2013-2023 59

Figure 7: SCT-Eligible Typical Patient Journey 65

Figure 8: Non-SCT-Eligible Typical Patient Journey 67

Figure 9: Velcade’s Phase III Development in Multiple Myeloma 95

Figure 10: Kyprolis’s Phase III Development in Multiple Myeloma 102

Figure 11: Revlimid’s Phase III Development in Multiple Myeloma 109

Figure 12: Pomalyst/Imnovid’s Phase III Development in Multiple Myeloma 116

Figure 13: Farydak’s Development in Multiple Myeloma 131

Figure 14: Dosing Schedule for Farydak 134

Figure 15: Ixazomib’s Development in Multiple Myeloma 137

Figure 16: Empliciti's Development in Multiple Myeloma 141

Figure 17: Daratumumab’s Development in Multiple Myeloma 148

Figure 18: Global Sales ($m) of Branded Products for Multiple Myeloma by Company, 2013 - 2023 163

Figure 19: Company Portfolio Gap Analysis in Multiple Myeloma, 2013-2023 164

Figure 20: Annual Global Sales for Multiple Myeloma by Region, 2013-2023 177

Figure 21: Annual Global Sales for Multiple Myeloma by Region - 2013, 2023 178

Figure 22: Annual Global Sales for Multiple Myeloma by Drug, 2013-2023 180

Figure 23: Global Sales for Multiple Myeloma by Drug, 2013 - 2023 181

Figure 24: Annual US Sales for Multiple Myeloma by Drug, 2013-2023 186

Figure 25: US Sales for Multiple Myeloma by Drug, 2013 and 2023 187

Figure 26: Annual 5EU Sales for Multiple Myeloma by Region, 2013-2023 193

Figure 27: Annual 5EU Sales for Multiple Myeloma by Drug, 2013-2023 194

Figure 28: 5EU Sales for Multiple Myeloma by Drug, 2013 and 2023 195

Figure 29: Annual Japanese Sales for Multiple Myeloma by Drug, 2013-2023 201

Figure 30: Japanese Sales for Multiple Myeloma by Drug, 2013 and 2023 202

Figure 31: Annual Chinese (Urban) Sales for Multiple Myeloma by Drug, 2013-2023 206

Figure 32: Chinese (Urban) Sales for Multiple Myeloma by Drug, 2013 and 2023 207

Additional Details

Publisher

Global Data

Publisher Information

Reference

17995 | GDHC114PIDR

Number of Pages

262

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025
PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025SummaryGlobalData estim...
01 May 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cel...
21 Apr 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024SummaryPsoriasis (PsO) is a...
13 Apr 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024SummaryBipolar disor...
01 Mar 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024...
01 Jan 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024SummaryDry Eye Syn...
05 Nov 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...